Advanced Platelet-rich Fibrin Combined With Open Debridement in Management of Suprabony Periodontal Defects

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1. 1This trial combined Advanced Platelet-rich Fibrin with open debridement for suprabony periodontal defects — how does that approach compare to what you'd recommend for my specific type of periodontitis, and is open debridement alone still a reasonable option for me?
2. 2Since this was a Phase 4 trial, meaning the treatments involved are already established, does that mean there's more known about the safety profile of Advanced Platelet-rich Fibrin compared to earlier-phase studies, and how does that affect your confidence in recommending it?
3. 3The trial focused on clinical evaluation as its primary outcome — do you know what specific clinical measures they tracked, like pocket depth or attachment levels, and how those results might relate to my current periodontal condition?
4. 4Since this trial has already been completed, have the results been published anywhere, and could we review the findings together to understand whether this combination approach showed any meaningful benefit over standard treatment?
5. 5If this trial's approach isn't right for me right now, what standard-of-care treatments for suprabony periodontal defects would you suggest we consider first before looking at any regenerative options?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.